Evidence map›Paper›PMID 35417924›Full record

ArticleCancer2022

Mortality among patients with low-grade follicular lymphoma: A binational retrospective analysis.

Aino Rajamäki, Mika Hujo, Reijo Sund, Roosa E I Prusila, Milla E L Kuusisto, Hanne Kuitunen, Esa Jantunen, Santiago Mercadal, Marc Sorigue, Juan-Manuel Sancho and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Aino RajamäkiDepartment of Oncology, Central Finland Central Hospital, Jyväskylä, Finland.ORCID 0000-0003-1105-3549
Mika HujoUniversity of Eastern Finland, Kuopio, Finland.
Reijo SundUniversity of Eastern Finland, Kuopio, Finland.
Roosa E I PrusilaUniversity of Oulu and Oulu University Hospital, Oulu, Finland.ORCID 0000-0002-8908-1542
Milla E L KuusistoUniversity of Oulu and Oulu University Hospital, Oulu, Finland.
Hanne KuitunenDepartment of Oncology, Oulu University Hospital, Oulu, Finland.
Esa JantunenUniversity of Eastern Finland, Kuopio, Finland.
Santiago MercadalInstitut Català d'Oncologia-Hospital Duran i Reynals, L'Hospitalet, Spain.
Marc SorigueDepartment of Hematology, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Functional Cytomics-Institut Josep Carreras, Badalona, Spain.
Juan-Manuel SanchoDepartment of Hematology, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Functional Cytomics-Institut Josep Carreras, Badalona, Spain.
Kaisa SunelaDepartment of Oncology, Tampere University Hospital, Tampere, Finland.
Outi KuittinenUniversity of Eastern Finland, Kuopio, Finland.
University of Eastern Finland · FIInstitut Català d'Oncologia · ESOulu University Hospital · FITampere University Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe life expectancy of patients with follicular lymphoma (FL) has improved considerably since the introduction of rituximab. This study examined the proportion of deaths from progressive lymphoma and the impact of FL on survival compared with that in the general population.

methodsAltogether, 749 patients with grades 1 and 2 FL in 9 institutions between 1997 and 2016 were enrolled. Competing risk models were used to estimate the cumulative incidences of deaths from progressive lymphoma and from other reasons. Excess mortality was analyzed with respect to the corresponding background populations standardized for age and sex using the excess mortality model based on the penalized spline approach.

resultsThe median follow-up duration was 69 months (range, 0-226 months). The estimated 10-year overall, disease-specific, and net survival rates were 72.4%, 86.6%, and 86.4%, respectively. The cumulative incidence of deaths from progressive lymphoma was slightly smaller than that of other causes in the study population (estimated 10-year cumulative incidences: 12.3% [95% CI, 9.6%-15.3%] and 15.4% [95% CI, 12.2%-18.8%], respectively). Excess mortality was observed for up to 10 years after diagnosis, and it slightly increased with time.

conclusionsDeaths from progressive lymphoma are nearly as common as deaths from other causes in FL patients during the rituximab era. Despite the improvements in survival, there was evidence of excess mortality resulting from FL for at least 10 years after diagnosis.

Indexed as

Lymphoma, FollicularAntineoplastic Combined Chemotherapy ProtocolsHumansRetrospective StudiesRituximabSurvival RateRituximabcause of deathfollicular lymphomamortalitysurvivalsurvival rate

Identifiers

PMID35417924
PMCPMC9325396
OpenAlexW4223934984

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.